NEW YORK, NY — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab...
Latest News
NEW YORK, NY — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This...
BOSTON, Mass. — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the...
Tokyo, Japan – Chromosome 18q deletion (18q del) syndrome is a rare genetic condition disorder, affecting approximately 1 in 40,000 to 55,000 individuals, caused by the deletion of genetic material on the long arm of chromosome 18. This genetic anomaly disrupts normal growth and development, and critically, can impair the...
Berlin, Germany – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, is pleased to announce a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12...
ST. LOUIS, MO – Each year, tuberculosis (TB) kills more people than any other infectious disease, falling out of the top spot only temporarily during the COVID-19 pandemic. Despite TB’s wide reach and some lost progress during the COVID-19 pandemic, researchers believe it is possible to eradicate TB through advances...
ANDERSON — “Every day is so different,” said Amanda Pfeiffer of Anderson. Pfeiffer was referring to her infant son, Kohen, who lives with a condition known as epidermolysis bullosa. “Like right now, he can’t be out in the heat and humidity, because it makes him blister really easily. It’s an...
AUSTIN, Texas — TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to TOBY’s urine-based Multi-Cancer Early Detection (MCED) test. The designation recognizes the test’s potential to enable earlier detection of multiple cancers through a...
Little Emma Gardner will have to take daily medication for the rest of her life after being born with a deadly genetic condition. Two-year-old Emma was diagnosed when she was just eight-weeks-old with cystic fibrosis, which affects her breathing and digestive system. Sufferers on average live only until their 30s...
Arlington, Va. — A new study published today in the American Journal of Infection Control (AJIC) reports the infection prevention steps taken to control a months-long multispecies outbreak of carbapenemase-producing Enterobacterales that occurred in a pediatric ward at the Toho University Omori Medical Center in Tokyo in 2017. This study...